Navigation Links
Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
Date:11/28/2007

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab

COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today recruitment of 132 patients has been completed in a pivotal study of ofatumumab (HuMax-CD20(R)) for the treatment of refractory chronic lymphocytic leukemia (CLL). This cohort comprises 66 patients who are refractory to both fludarabine and alemtuzumab and 66 fludarabine refractory patients who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An interim analysis will be conducted on this cohort when 24 week efficacy data are available. The study will remain open for recruitment in order to collect additional safety and efficacy data.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of b-cells. This epitope is different to the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"We look forward to seeing the study results of the interim analysis from both patient groups. It is our hope, due to the high unmet need amongst these patients, that registration may be possible in each indication, depending on the data generated and ongoing discussions with the regulatory authorities. Recruitment will continue to the trial," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the study

The study includes CLL patients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. Each group will be analyzed separately and it is hoped that, registration of ofatum
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... YORK , May 5, 2015 ... announced that Andrew Gengos , President and Chief ... May 7, 2015. DATE:  Thursday, May 7, ... LINK:  http://VirtualInvestorConferences.com > click the red ... be a live, interactive online event where investors ...
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Synedgen Inc. ... PhD as Regulatory Affairs Manager. , Dr. Nguyen brings ... important juncture for the company as it moves forward ... products over the next two years. Dr. Nguyen will ... all the regulatory key documents that must be completed ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2
... May 8 Exelixis,Inc. (Nasdaq: EXEL ) announced ... officer of Exelixis, will present at the Bank of,America ... PT on,Tuesday, May 13, 2008. Dr. Scangos will discuss ... The presentation will be webcast and may be accessed ...
... 8 Informed Clinical Sciences (ICS) Advisory,Services ... company,s three-part,Intellectual Property (IP) platform. This Platform ... Informatics Review, an Alliance Business,Review, and a ... the sciences,business concerns, and enabling technologies underlying ...
... Also Announces CE Mark Approval for First Product, the CorMatrix ... ECM(TM) ... Inc., an,Atlanta- based company dedicated to developing and delivering unique,extracellular ... repair damaged cardiovascular tissue, announced,today that the company has received ...
Cached Biology Technology:IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance 2IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... experts from the University of Leicester have teamed up ... space technology for earth-bound benefits. A Space Technology ... support business and public sector organisations use state-of-the-art Earth ... launched on 19th June 2009 at the University of ...
... Rice University scientists warned that the United States must ... as an alternative to imported oil takes into account ... ongoing, rapid growth in biofuels production could have far-reaching ... the interdependence and growing tension between energy and water ...
... the brain that plays a key role in the function ... energy, supports cellular activity, and potentially wards off threats from ... Journal of Cell Biology , may shed new light ... "Understanding the molecular machinery that helps distribute mitochondria to different ...
Cached Biology News:'Platforms in space' to help businesses 2'Platforms in space' to help businesses 3Rice University researchers ask if biofuels will lead to a 'drink or drive' 2Protein regulates movement of mitochondria in brain cells 2Protein regulates movement of mitochondria in brain cells 3
...
...
...
... Application: The greater incorporation of Br-dUTP results ... when detected using a fluorescein-labeled anti-BrdU antibody. ... in the kit to counterstain the total ... Br-dUTP, resulting in improved detection than found ...
Biology Products: